Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has The Hereditary Angioedema Market Growth Evolved From 2024 To 2025, And What’s Ahead?

The market size of hereditary angioedema has seen robust growth in recent years. It’s anticipated to expand from $2.62 billion in 2024 to $2.81 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 7.4%. The growth experienced in the previous period was due to several factors, including a rise in instances of hereditary angioedema, larger investments in R&D, an increasing amount of approved drugs, increased product approvals, and a growth in disposable income.

The market size of hereditary angioedema is projected to witness impressive expansion in the upcoming years. The market is expected to reach$3.84 billion by 2029, with a compound annual growth rate (CAGR) of 8.1%. The growth during the forecast period can be credited to the escalating occurrence of rare diseases, augmented expenditure on healthcare, increased backing from non-profit entities, improved understanding of hereditary angioedema, and the growing consciousness about early disease detection. Major trends expected during the forecast period include technological evolution, emergence of unique therapies, introduction of novel drugs, advanced diagnostic methodologies, and progress in genetic testing.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22002&type=smp

Which Factors and External Forces Are Driving Demand in the Hereditary Angioedema Market?

The escalating occurrence of rare maladies is projected to spur the expansion of the hereditary angioedema market. Rare illnesses, also described as orphan diseases, are medical disorders that impact a minor fraction of the populace. This increasing occurrence is attributed to various factors like advances in medical studies, shifts in demographic patterns, and environmental influences. Hereditary angioedema (HAE) is a significant orphan disease, accentuating the requirement for specialized intervention and awareness due to its potentially fatal swelling events. Its uniqueness and genetic characteristic necessitate early detection and precise treatments for effective control and enhanced patient results. For example, in June 2022, as per Rising Disease Advisor, a US-origin online resource firm catering to healthcare providers, hereditary angioedema (HAE) has an impact on approximately 1 in 50,000 individuals, with approximations of occurrence ranging from 1 in 10,000 to 1 in 150,000. In America, HAE incidents result in about 15,000 to 30,000 emergency unit visits each year. Hence, the rising occurrence of rare maladies is propelling the expansion of the hereditary angioedema market.

Which Segments in the Hereditary Angioedema Offer the Most Growth?

The hereditary angioedemamarket covered in this report is segmented –

1) By Type: Hereditary Angioedema Type I; Hereditary Angioedema Type II

2) By Treatment Type: Prophylaxis; On-demand

3) By Drug Class: C-1 Esterase Inhibitors; Bradykynin Receptor Antagonist; Kallikrein Inhibitors; Other Drug Classes

4) By Route Of Administration: Subcutaneous; Intravenous; Oral

5) By Distribution channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Subsegments:

1) By Hereditary Angioedema Type I: C1-Inhibitor Deficiency; Low C1-Inhibitor Levels; Reduced C1-Inhibitor Function

2) By Hereditary Angioedema Type II: Normal C1-Inhibitor Levels; Dysfunctional C1-Inhibitor; Genetic Mutations In SERPING1 Gene

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=22002&type=smp

What Are the Fastest-Growing Geographies in the #Which Factors and External Forces Are Driving Demand in the Hereditary Angioedema Market?# Market?

North America was the largest region in the hereditary angioedema market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Cutting-Edge Market Trends Are Expected to Drive theHereditary Angioedema Market’s Growth?

Major firms operating within the hereditary angioedema market are introducing inventive products like oral plasma kallikrein inhibitors. These inhibitors are designed to offer more efficient and accessible treatment options for patients. Primarily, they are used to treat hereditary angioedema by blocking plasma kallikrein to halt excessive bradykinin production. In September 2024, for example, US-based KalVista Pharmaceuticals, Inc. shared that the FDA had accepted its new drug application (NDA) for sebetralstat. This novel oral plasma kallikrein inhibitor is purposed for treating hereditary angioedema (HAE) attacks in both adult and pediatric patients aged 12 and over. Sebetralstat heralds a new form of treatment by obstructing plasma kallikrein activity. The acceptance of the NDA by the FDA is a significant step forward towards potential authorization and commercialization.

View the full report here:

https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-global-market-report

What Are the Key Elements That Define the Hereditary Angioedema Market?

Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of severe swelling in the skin, gastrointestinal tract, and airways due to C1 esterase inhibitor deficiency or dysfunction. It is caused by genetic mutations affecting the complement system, leading to excessive bradykinin production. HAE can be life-threatening if airway swelling occurs, requiring prompt treatment with C1 inhibitor replacement or bradykinin-targeted therapies.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22002

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model